DelveInsight Business Research LLP

Retatrutide vs Wegovy vs Zepbound: The New Era of Obesity Therapeutics The obesity treatment landscape is evolving rapidly, with next-generation incretin therapies reshaping the pharmaceutical market and patient outcomes. Retatrutide: The Triple Agonist Challenger Developed by Eli Lilly and Company, Retatrutide is gaining major industry attention due to its triple hormone receptor targeting mechanism (GLP-1, GIP, and glucagon receptors). Key Highlights: • Clinical studies have demonstrated up to ~28% weight reduction in patients • Potential benefits beyond weight loss, including metabolic and cardiovascular improvements • Emerging as a strong contender in the next-generation obesity drug market Wegovy: The Established Market Leader Novo Nordisk’s Wegovy (semaglutide) continues to dominate the obesity market with strong physician adoption and expanding global demand. Market Strengths: • Proven efficacy and extensive real-world evidence • Strong brand recognition globally • Continued expansion into cardiovascular and metabolic indications Zepbound: Rapidly Expanding Competition Zepbound (tirzepatide), also from Eli Lilly and Company, has quickly become one of the most discussed obesity therapies in the pharma industry. Why It’s Trending: • Dual GIP/GLP-1 mechanism driving superior weight-loss outcomes • Increasing adoption across obesity and diabetes management • Significant commercial growth potential in the anti-obesity therapeutics segment What This Means for the Pharma Market The obesity therapeutics space is now one of the fastest-growing pharmaceutical sectors globally, driven by: - Rising obesity prevalence - Expanding payer coverage - Innovation in incretin-based therapies - Strong clinical trial momentum - Growing investor and biotech interest How DelveInsight Supports Strategic Market Intelligence DelveInsight helps pharmaceutical, biotech, and healthcare organizations with: • Comprehensive market research reports • Competitive intelligence analysis • Pipeline assessment and forecasting • Clinical trial tracking • Emerging therapy insights • Strategic business decision support Want deeper insights into the obesity therapeutics market, GLP-1 pipeline trends, and competitive landscape? Connect with DelveInsight today to access actionable pharma intelligence and market forecasts. https://lnkd.in/gCQnhBqg #ObesityMarket #Retatrutide #Wegovy #Zepbound #GLP1 #Pharma #Biotech #WeightLossDrugs #ClinicalTrials #PharmaceuticalIndustry #HealthcareInnovation #MarketResearch #DelveInsight

This week's #MedTechNews highlights six significant milestones across oncology, radiology, diagnostics and others: Leo Cancer Care announced that its flagship upright radiotherapy platform, Marie, has secured CE Mark approval, paving the way for commercial rollout across Europe. PorTal Access, Inc. completed its U.S. FDA 510(k) submission for Flexi-Port, the company’s lead vascular access device. Araceli Biosciences launched Endeavor Live Cell, extending its ultra-high-throughput imaging platform into live-cell and dynamic biology applications at screening scale. TrilliumBiO and Oncobit AG introduced Oncular™ in the U.S., expanding access to Oncobit’s uveal melanoma monitoring solution through TrilliumBiO’s multi-accredited laboratory network. Advita Ortho reported the first clinical use of the Equinoxe Scapula Reconstruction System, the first dedicated trauma solution designed for acromial and scapular spine fractures and non-unions, including cases linked to reverse shoulder arthroplasty. Implantica highlighted new study findings showing that RefluxStop, its novel GERD treatment device, delivers strong cost-effectiveness versus conventional GERD therapies in the Italian healthcare system. Read the full roundup and discover what's shaping the future of medical technology at: https://lnkd.in/dTk__wXV #MedTech #Biotech #HealthcareInnovation #MedicalDevices #Radiotherapy #FDA #CEMarking #Oncology #CancerCare #Diagnostics #Orthopedics #GERD #DigitalHealth #LifeSciences

Plasmid DNA manufacturing has evolved far beyond a supporting technical function; it is now a foundational pillar of next-generation medicine. As healthcare shifts from symptom management toward genetic correction, gene editing, and cellular reprogramming, plasmid DNA has become central to therapeutic innovation and value creation. The global plasmid DNA manufacturing market is projected to grow from USD 2.46 billion in 2025 to USD 10.86 billion by 2034, reflecting robust long-term expansion at a CAGR of 18.06% during 2026–2034. Key players shaping the market include Thermo Fisher Scientific, Charles River Laboratories, Lonza, Aldevron, GenScript ProBio, AGC Biologics, Catalent, WuXi AppTec, Eurogentec, Sartorius, Pharmaron, VectorBuilder, and several others, driving innovation and manufacturing scale globally. Organizations capable of delivering scalable, regulatory-compliant, and high-purity plasmid DNA manufacturing solutions will be instrumental in enabling the next wave of gene and cell therapies. Explore more about plasmid DNA manufacturing at: https://lnkd.in/gipZAGEF #PlasmidDNA #GeneTherapy #CellTherapy #Biotech #Biopharma #DNAManufacturing #GeneticMedicine #mRNA #CGT #LifeSciences #Biotechnology

Today is National Asian and Pacific Islander HIV/AIDS Awareness Day!! 2.2% of new U.S. HIV diagnoses occur among Asian, Native Hawaiian, and Pacific Islander communities, a number that reminds us awareness, access, and action still matter. This May 19th, let's commit to: Knowing our status — get tested, stay informed Protecting our health — PrEP and PEP are effective tools Supporting our communities — because ending HIV is a collective effort Breaking stigma starts with open conversations. Share this to spread awareness and stand in solidarity with the #AANHPI community. #HIVAwareness #AAPIHealth #NationalAAPIHIVAIDSAwarenessDay #NAPIHAAD #EndHIV #HealthEquity

Big week in pharma deals & breakthroughs! This week's #PharmaNews spotlights five major milestones shaping the future of medicine: AstraZeneca’s BAXFENDY has secured U.S. approval as the first aldosterone synthase inhibitor (ASI) indicated for adults with hypertension whose blood pressure remains uncontrolled despite treatment with other antihypertensive medications. Regeneron reported Phase III results showing that a first-line regimen incorporating its LAG-3 inhibitor #fianlimab achieved numerically longer progression-free survival (PFS) than Merck & Co.’s #KEYTRUDA in certain melanoma patients; however, the difference did not reach statistical significance. AstraZeneca and Daiichi Sankyo US announced that ENHERTU has been approved by the U.S. Food and Drug Administration for both neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer. These approvals were based on results from the Phase III DESTINY-Breast11 and DESTINY-Breast05 studies, respectively. REGENXBIO announced positive topline and interim functional findings from the pivotal Phase III segment of the Phase I/II/III AFFINITY DUCHENNE® study evaluating #RGX-202, its investigational gene therapy candidate for #DuchenneMuscularDystrophy. BeOne Medicines announced that the #FDA has granted accelerated approval to #BEQALZI, its next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) who have previously received at least two lines of systemic therapy, including a BTK inhibitor. Read the full roundup and stay ahead of what's next in pharma at: https://lnkd.in/gNwmcmqM #DrugDiscovery #ClinicalTrials #Oncology #RareDiseases #FDAApproval #LifeSciences

Multiple myeloma continues to rank among the most complex and difficult-to-treat hematologic malignancies, yet the therapeutic landscape is evolving rapidly. Valued at nearly USD 28.7 billion in 2025, the multiple myeloma market is expected to witness sustained growth through 2036, fueled by one of the strongest pipelines the space has seen to date. Seven late-stage candidates are now approaching potential regulatory approval, including Arcellx/Gilead Sciences’ Anito-cel, AbbVie’s ABBV-383, Bristol Myers Squibb/Celgene’s Iberdomide, Mezigdomide, and Arlo-cel, AbbVie and Roche’s VENCLEXTA, and AstraZeneca’s AZD0120. Together, these therapies highlight a new wave of innovation, leveraging diverse mechanisms and next-generation approaches to address the persistent unmet needs in this still-incurable disease. Dive deep into the detailed assessment of which therapy is poised to lead the next era in multiple myeloma treatment at: https://lnkd.in/gj3n254u #MultipleMyeloma #Oncology #CancerResearch #Biotech #Pharma #Immunotherapy #CellTherapy #BispecificAntibodies #DrugDevelopment #ClinicalTrials #Hematology

The HER2+ NSCLC treatment landscape is evolving rapidly with breakthrough targeted therapies, ADCs, and promising late-stage pipeline candidates transforming patient outcomes. From #ENHERTU to next-generation HER2-specific TKIs like zongertinib, innovation continues to reshape the future of precision oncology in lung cancer. Emerging clinical data and expanding regulatory approvals are opening new opportunities in this aggressive #NSCLCsubtype. Explore DelveInsight’s latest insights on HER2+ NSCLC market trends, epidemiology, and emerging therapies: HER2+ NSCLC Treatment Landscape Blog https://lnkd.in/g-Jwjz6f #NSCLC #LungCancer #HER2 #Oncology #CancerResearch #PrecisionMedicine #Biotech #Pharma #HealthcareInnovation

This week's #MedTechNews highlights six significant milestones across urology, cardiology, diagnostics and others: Aurie announced that the U.S. Food and Drug Administration (FDA) had granted marketing authorization for its Aurie Reusable No-Touch Intermittent Catheter System™ through the Class II De Novo pathway. Biozen announced that the U.S. Food and Drug Administration (FDA) had granted 510(k) clearance to its #BP1000, making it the first cuffless blood pressure device in the United States capable of providing calibration-free, clinically validated spot measurements from the fingertip. PlusOne® announced the expansion of its Wellness Care Collection with the introduction of two purpose-driven lubricants developed to support women through various life stages, including fertility and menopause. TrilliumBiO and Oncobit AG announced the launch of Oncular™, enabling the availability of Oncobit’s uveal melanoma monitoring solution in the United States through TrilliumBiO’s multi-accredited laboratory. Renerva, Inc. announced the implantation of the first patient in its first-in-human clinical study evaluating the Renerva PNM-CAP™ device. SonoClear AS announced the completion of the final clinical procedure in its study assessing the #SonoClearSystem for intracranial ultrasound procedures in patients with neurological tumors. Read the full roundup and discover what's shaping the future of medical technology at: https://lnkd.in/dZcy_A3E #MedicalDevices #HealthcareInnovation #MedTech2026 #CancerDiagnostics #LiquidBiopsy #WomenHealth

The AI in life sciences market is experiencing significant growth, with a CAGR of ~20% by 2034, driven by the increasing need for faster, more efficient drug discovery and development. Pharmaceutical and biotechnology companies are rapidly adopting AI-powered technologies to streamline research processes, shorten development timelines, and reduce costs associated with traditional R&D approaches. Simultaneously, the active participation of key companies such as Recursion, Insilico Medicine, Atomwise, Exscientia, BenevolentAI, NVIDIA, Medidata (Dassault Systèmes), Scispot, CYCLICA, Deep Genomics, Karyon Bio, Variant, Intel, Advanced Micro Devices, and others. Learn more at: https://lnkd.in/gANDMGyZ #AI #LifeSciences #ArtificialIntelligence #DrugDiscovery #Biotechnology #Pharma #DigitalHealth #HealthcareInnovation #PharmaceuticalIndustry #BiotechInnovation #PrecisionMedicine #FutureOfHealthcare

As per DelveInsight, the global colorectal cancer diagnostics and therapeutics market is experiencing significant growth at a CAGR of ~9% by 2034, driven by the increasing incidence of colorectal cancer, rising awareness around early detection, and continuous advancements in precision medicine. The expanding use of non-invasive diagnostic approaches, including liquid biopsy, stool DNA testing, and molecular diagnostics, is further contributing to market growth and improving patient outcomes. Key companies active in the space include Exact Sciences, Guardant Health, F. Hoffmann-La Roche Ltd., Abbott, QIAGEN, Illumina, Thermo Fisher Scientific, @Epigenomics AG, Eiken Chemical Co Ltd, Clinical Genomics Inc., VolitionRx Ltd., Siemens, and others. Explore more at: https://lnkd.in/g6k7msqX #ColorectalCancer #CancerDiagnostics #PrecisionMedicine #LiquidBiopsy #MolecularDiagnostics #Oncology #CancerTherapeutics #HealthcareInnovation #Biotech #EarlyDetection #CancerResearch #CRC #PersonalizedMedicine #HealthcareMarket #MedTech